Could a psychedelic compound help smokers quit for good?
NCT ID NCT05452772
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether psilocybin, a psychedelic substance, can help people stop smoking. Sixty-six daily smokers who have tried and failed to quit before will receive either psilocybin or niacin (a vitamin) in two sessions one week apart. Researchers will check if participants have remained smoke-free after 12 months using self-reports and biological tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If successful, this could point toward a new treatment option for tobacco use disorder, helping people quit smoking more effectively.
What could go wrong
This is a phase 2 trial with only 66 participants, so results may not apply to everyone. Psilocybin can cause intense psychological effects, and the study compares it to niacin, not a standard cessation therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOBACCO USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University School of Medicine
ACTIVE_NOT_RECRUITINGBaltimore, Maryland, 21224, United States
-
New York University
ACTIVE_NOT_RECRUITINGNew York, New York, 10016, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••